Zobrazeno 1 - 10
of 124
pro vyhledávání: '"Roberta A Jorgensen"'
Autor:
Andrea A. Gossard, Alisha C. Stahler, Marina G. Silveira, Keith D. Lindor, Janice L. Petz, Ahmad H. Ali, Roberta A. Jorgensen
Publikováno v:
American Journal of Therapeutics. 24:e167-e176
Background and aims Fatigue is a common symptom of primary biliary cirrhosis (PBC), and is associated with an impaired quality of life. Study question No studies have assessed the use of modafinil in fatigue related to PBC in a controlled manner. Stu
Autor:
James H. Tabibian, John E. Eaton, Andrea A. Gossard, Anilga Tabibian, Jan Petz, Keith D. Lindor, Mounif El-Youssef, Felicity B. Enders, Roberta A. Jorgensen
Publikováno v:
American Journal of Therapeutics. 24:e56-e63
Primary sclerosing cholangitis (PSC) is a rare, chronic, cholestatic liver disease in which emerging data suggest that oral antibiotics may offer therapeutic effects. We enrolled patients with PSC in a 12-week, open-label pilot study to investigate t
Autor:
Keith D. Lindor, Evangelos Kalaitzakis, Matthias Neuhauser, Roberta A. Jorgensen, Einar Björnsson, Jayant A. Talwalkar, Roger W. Chapman, Felicity Enders, Hardy Maetzel
Background: Fatigue was recently suggested to predict an increased risk of mortality in a primary biliary cirrhosis (PBC) cohort during follow-up. Aims: To analyse the impact of fatigue on prognosis in PBC. Methods: Patients with PBC who had earlier
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::498f8387dcd261c791f236f7a46d9221
https://doi.org/10.1111/j.1478-3231.2009.02160.x
https://doi.org/10.1111/j.1478-3231.2009.02160.x
Publikováno v:
Digestive and Liver Disease. 44:44-48
Background Limited data are available regarding the serum lipids in primary sclerosing cholangitis. Aims To determine the lipid levels in patients with primary sclerosing cholangitis. Methods We monitored the serum lipid levels annually for up to 6 y
Publikováno v:
Liver International. 32:790-795
Background Biochemical tests have been recommended as endpoints for clinical trials in primary biliary cirrhosis (PBC) because the use of liver transplantation and death as endpoints in ursodeoxycholic acid (UDCA) therapeutic trials is unfeasible. Th
Autor:
Keith D. Lindor, Kris V. Kowdley, Andrea A. Gossard, Denise M. Harnois, Jill C. Keach, Emmanouil Sinakos, Mohamad Imam, Alisha C. DeCook, Timothy M. McCashland, M. Edwyn Harrison, Velimir A. Luketic, Jan Petz, Roberta A. Jorgensen, Felicity Enders, Alex S. Befeler
Publikováno v:
Alimentary Pharmacology & Therapeutics. 34:1185-1192
Aliment Pharmacol Ther 2011; 34: 1185–1192 Summary Background Ursodeoxycholic acid (UDCA) in a dose of 28–30 mg/kg/day increases the likelihood of clinical deterioration of primary sclerosing cholangitis (PSC) patients. Aim To compare the risk of
Autor:
Emmanouil Sinakos, M. Edwyn Harrison, Timothy M. McCashland, Kris V. Kowdley, Marina G. Silveira, Darrell S. Pardi, Jan Petz, Velimir A. Luketic, John E. Eaton, Alex S. Befeler, Keith D. Lindor, Roberta A. Jorgensen, Denise M. Harnois
Publikováno v:
American Journal of Gastroenterology. 106:1638-1645
Some studies have suggested that ursodeoxycholic acid (UDCA) may have a chemopreventive effect on the development of colorectal neoplasia in patients with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC). We examined the effects of hi
Autor:
Paul Angulo, Ayako Suzuki, Jill C. Keach, Michael Charlton, James F. Lymp, Jan Petz, Keith D. Lindor, Roberta A. Jorgensen
Publikováno v:
Food and Nutrition Sciences. :67-73
Background: Mitochondrial dysfunction plays a pivotal role in the progression of nonalcoholic steatohepatitis (NASH). L-alanine was shown to restore ATP content and protect the liver in various liver injury models. Aim: To assess the safety and thera
Autor:
Keith D. Lindor, Janice L. Petz, Jayant A. Talwalkar, Roberta A. Jorgensen, Phunchai Charatcharoenwitthaya, Andrea A. Gossard, Jill C. Keach, Paul Angulo
Publikováno v:
Digestive Diseases and Sciences. 55:476-483
Blockade of angiotensin II synthesis attenuates hepatic fibrosis in different experimental models of chronic liver injury. We evaluated the safety and efficacy of moexipril, an angiotensin-converting enzyme inhibitor, in patients with primary biliary
Autor:
Marina G. Silveira, RN Janice L Petz, Keith D. Lindor, Natalie J. Török, Roberta A. Jorgensen, Jill C. Keach, Andrea A. Gossard
Publikováno v:
The American Journal of Gastroenterology. 104:83-88
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of young adults that is associated with significant morbidity and mortality. No effective medical therapy is available. Minocycline has been found to exert biological effects